Live
FierceBiotechEmbecta to buy auto-injector maker Owen Mumford for $200M to diversify beyond insulinIlluminaA Look At Labcorp Holdings (LH) Valuation After Expanded Illumina Precision Oncology Alliance - simplywall.stLonza NewsLonza Group AG stock faces pressure amid Swiss trade data and transformation completion - AD HOC NEWSEndpoints NewsTech talent comes to healthcareCellThermodynamic prediction of RNA cellular activity from sequence via conformational ensemblesCellContextual computation by competitive protein dimerization networksCellTransplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson’s disease modelsFierceBiotechPfizer adds to Seagen scrap heap with another early cancer candidate cullFierceBiotechGenentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failureScienceDebate explodes over age of key South American archaeological siteScienceWhat happened when an Arab neuroscientist took the helm at an Israeli university?BioPharma DiveNovo uses FDA voucher to win speedy approval of higher-dose Wegovy
PLoS Biology Jan 26, 2026

Dose-dependent activation of the Hippo pathway by Type I and Type III interferons suppresses tissue repair by human bronchial epithelial cells

Dose-dependent activation of the Hippo pathway by Type I and Type III interferons suppresses tissue repair by human bronchial epithelial cells

Original
Body unavailable. Use the original source.

Directory

59 All